This information might reinforce the association of HER2-expressing cells with poorer outcomes, likewise reported in other HER2-positive studies in women with BC that received trastuzumab as NAC (38% pCR rate) [19,20]. Other studies on the HER-positive population suggested higher rates of pCR when using pertuzumab added to trastuzumab emtasine, docetaxel, and carboplatin (55%) [21]. This evidence concerns the gene ERBB2 and breast cancer.